Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS)
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, non-randomized, controlled intervention clinical
study.Patients with severe fever with thrombocytopenia syndrome who have been clinically
diagnosed and met the study inclusion criteria will be included in the study for analysis.
All patients with SFTS will be assigned to different groups according to the ratio of 1:3,
including the non-intervention group (conventional treatment group) and the related drug
intervention group.
Non-intervention group:patients received standard care during hospitalization.
Intervention group:
Part A group: Patients received methylprednisolone 2mg/kg/d + intravenous immunoglobulin
(IVIG) 20g/d for a total of 5 days. If the disease progressed after treatment, the patients
was given the dose of rescue therapy (methylprednisolone > 2mg/kg/d + IVIG 20g/d) for another
5 days.
Part B group: Patients received tocilizumab 4mg/kg once. Part C group: Patients received low
molecular weight heparin 100U/kg, q12h IH for 7 days.
All patients were followed up from the end of treatment to day 28 after completion of
treatment.